Gossamer Bio
GOSS
96 hedge funds and large institutions have $410M invested in Gossamer Bio in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 27 increasing their positions, 30 reducing their positions, and 11 closing their positions.
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
9% more funds holding
Funds holding: 88 → 96 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.25% less ownership
Funds ownership: 61.2% → 60.95% (-0.25%)
10% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 30
35% less capital invested
Capital invested by funds: $632M → $410M (-$221M)
70% less call options, than puts
Call options by funds: $1.09M | Put options by funds: $3.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$19.7M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.77M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.56M |
| 4 |
AG
Artal Group
Luxembourg
|
+$2.61M |
| 5 |
Morgan Stanley
New York
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$24.1M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$5.22M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$4.23M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$1.66M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$1.51M |
GOSS Hedge Fund Activity: Q1 2020 in Review
96 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q1 2020, worth a combined $410M — down 35% from $632M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new GOSS positions and 11 closed out — a net gain of 10 holders — while 27 added to existing stakes and 30 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $19.7M. The largest seller was Omega Fund Management, cutting an estimated $24.1M.
- 96 institutional investors held Gossamer Bio (GOSS) as of Q1 2020, up from 88 in Q4 2019.
- Funds reported $410M of Gossamer Bio stock for Q1 2020, down 35% quarter-over-quarter.
- 21 funds opened new Gossamer Bio positions in Q1 2020 and 11 closed out, a net change of +10 holders.
- The largest Gossamer Bio buyer in Q1 2020 was Victory Capital Management, an estimated $19.7M added.
- The largest Gossamer Bio seller in Q1 2020 was Omega Fund Management, an estimated $24.1M sold.
Based on aggregated 13F filings for Q1 2020.